Northwestern Mutual Wealth Management
PMCB icon

Northwestern Mutual Wealth Management’s PharmaCyte Biotech PMCB Stock Holding History

Northwestern Mutual Wealth Management’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-14
Closed -$30 – 3758
2023
Q4 		$30 Buy
+14
New +$30 ﹤0.01% 3420

Other funds holding PMCB

KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Northwestern Mutual Wealth Management's PMCB Position: Q1 2024 in Review

Northwestern Mutual Wealth Management sold out of PharmaCyte Biotech (PMCB) in Q1 2024, closing a stake of 14 shares — an estimated $30 sold.

Northwestern Mutual Wealth Management first reported a position in PMCB in Q4 2023 and held it in 1 quarter. The position peaked at $30 in Q4 2023. 29 funds tracked by Wall St. Rank hold PMCB as of Q1 2024.

  • Northwestern Mutual Wealth Management reported no remaining PharmaCyte Biotech position as of Q1 2024 after selling out during the quarter.
  • Northwestern Mutual Wealth Management sold 14 PharmaCyte Biotech shares in Q1 2024, an estimated $30.
  • Northwestern Mutual Wealth Management first reported a position in PharmaCyte Biotech in Q4 2023 and held it in 1 quarter.
  • Northwestern Mutual Wealth Management's PharmaCyte Biotech position peaked at $30 in Q4 2023.
  • 29 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2024.

Based on Northwestern Mutual Wealth Management's 13F filing for Q1 2024, filed 15 May 2024.